Maria. M. Bernardi

Suggest Changes
Learn More
Hemorrhagic events remain the most worrisome complication in patients receiving drugs that alter hemostasis for treatment of acute coronary syndromes. The 7E3 Fab monoclonal antibody provides a(More)
  • 1